Delving into the Latest Updates on FIBREX Medical, Inc. with Synapse

Overview

A review.FX06 (fibrin derived peptide Bβ15-42) is a promising new drug candidate indicated for the prevention of reperfusion injury in patients undergoing primary percutaneous intervention (PCI) for acute myocardial infarction (AMI).This novel peptide has been shown to prevent myocardial reperfusion injury in a number of acute and chronic animal models for this disease when given as a single bolus injection at the time of reperfusion.FX06 has a novel mechanism of action: it is a competitive inhibitor of the binding of fibrin E1 fragments to vascular endothelial (VE)-cadherin.Through this inhibition, it potently blocks the transmigration of inflammatory leukocytes through the endothelial barrier and prevents the downstream release of tissue-damaging mediators.FX06 has proven safe in acute and subchronic toxicol. studies and recently entered clin. development.

100 Deals associated with FIBREX Medical, Inc.

Login to view more data

100 Translational Medicine associated with FIBREX Medical, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data